MNLO Menlo Therapeutics Inc.

2.39
-0.29  -11%
Previous Close 2.68
Open 2.56
Price To Book 2.13
Market Cap 146,029,000
Shares 61,100,000
Volume 426,830
Short Ratio
Av. Daily Volume 639,661
Stock charts supplied by TradingView

NewsSee all news

  1. Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer

    BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company"), a biopharmaceutical company focused on developing and commercializing proprietary therapies to

  2. Menlo Therapeutics Provides a Business Update in the Context of COVID-19

    BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company"), a biopharmaceutical company focused on developing and commercializing proprietary therapies to

  3. Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019

    Foamix Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020 Menlo Conference Call and Webcast Scheduled for Thursday, March 12 at 8:30am Eastern Time BRIDGEWATER, N.J., March

  4. Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company") announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)

  5. Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

    REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial evaluating the safety and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date June 2, 2020.
FMX103
Papulopustular rosacea
FDA Approval announced October 18, 2019.
FMX101
Acne
Phase 3 planned.
Serlopitant
Pruritus associated with psoriasis
Phase 3 data due late-March/ early-April 2020.
Serlopitant
Pruritus associated with prurigo nodularis
Phase 2 data released October 8, 2018. Endpoints not met.
Serlopitant
Refractory chronic cough
Phase 2 data released April 9, 2018. Endpoints not met.
Serlopitant
Pruritus associated with atopic dermatitis
Phase 2 trial did not meet primary endpoint - February 26, 2020.
Serlopitant
Chronic pruritus of unknown origin
Phase 2 data due 2Q 2020.
FCD105
Acne

Latest News

  1. Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer

    BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company"), a biopharmaceutical company focused on developing and commercializing proprietary therapies to

  2. Menlo Therapeutics Provides a Business Update in the Context of COVID-19

    BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company"), a biopharmaceutical company focused on developing and commercializing proprietary therapies to

  3. Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019

    Foamix Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020 Menlo Conference Call and Webcast Scheduled for Thursday, March 12 at 8:30am Eastern Time BRIDGEWATER, N.J., March

  4. Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company") announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)

  5. Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

    REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial evaluating the safety and

  6. Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

    REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February

  7. Foamix and Menlo Announce Shareholder Approval of Proposed Merger

    REHOVOT, Israel and BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) and Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced that the

  8. Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),

  9. Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements

  10. Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),

  11. Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

    REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),